Date: 2011-07-26
Type of information: Production agreement
Compound: undisclosed therapeutic antibody
Company: Selexis (Switzerland) CSL (Australia)
Therapeutic area:
Type agreement: services
bioproduction
manufacturing
Action mechanism:
Disease:
Details: Selexis, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, has entered a commercial license agreement with CSL Limited for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.
This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis
SUREtechnology Platform, for the cGMP production of an undisclosed antibody. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
